Nurit Katz-Agranov
Overview
Explore the profile of Nurit Katz-Agranov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Katz-Agranov N, Rieu-Werden M, Thacker A, Lykken J, Sise M, Shah S
Clin J Am Soc Nephrol
. 2024 Aug;
19(10):1275-1283.
PMID: 39146034
No abstract available.
2.
Hanna P, Anumolu R, Motwani S, Chen K, Katz-Agranov N, Green-Lingren O, et al.
Kidney Int Rep
. 2024 Jun;
9(6):1897-1902.
PMID: 38899179
No abstract available.
3.
Hanna P, Ouyang T, Tahir I, Katz-Agranov N, Wang Q, Mantz L, et al.
J Cachexia Sarcopenia Muscle
. 2024 Apr;
15(3):1187-1198.
PMID: 38646842
Background: Creatinine-based estimated glomerular filtration rate (eGFR) may overestimate kidney function in patients with sarcopenia. While cystatin C-based eGFR (eGFR) is less affected by muscle mass, it may underestimate kidney...
4.
Mistry K, Zhao S, Strohbehn I, Wang Q, Hanna P, Strohbehn S, et al.
Nephrol Dial Transplant
. 2024 Feb;
39(6):1040-1043.
PMID: 38389257
No abstract available.
5.
Wang Q, Seethapathy R, Ouyang T, Strohbehn I, Katz-Agranov N, Hanna P, et al.
Kidney Int Rep
. 2023 Dec;
8(12):2833-2837.
PMID: 38106586
No abstract available.
6.
Hanna P, Strohbehn I, Moreno D, Harden D, Seethapathy R, Sawtell R, et al.
NPJ Breast Cancer
. 2023 Aug;
9(1):70.
PMID: 37598278
Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved overall and progression free survival of patients with metastatic breast cancer, but their effect on short and long-term kidney function is unknown....
7.
Hanna P, Wang Q, Strohbehn I, Moreno D, Harden D, Ouyang T, et al.
JAMA Netw Open
. 2023 Jul;
6(7):e2321715.
PMID: 37405775
Importance: Serum creatinine-based estimated glomerular filtration rate (eGFRcr) may overestimate the glomerular filtration rate (GFR) in patients with cancer. Cystatin C-based eGFR (eGFRcys) is an alternative marker of GFR. Objective:...
8.
Sise M, Katz-Agranov N, Strohbehn I, Harden D, Moreno D, Durbin C, et al.
J Acquir Immune Defic Syndr
. 2023 May;
94(1):53-56.
PMID: 37229530
Background: Sodium-glucose transporter 2 (SGLT2) inhibitors have been approved for treatment of diabetes mellitus (DM), chronic kidney disease, and heart failure, but little is known about prescription levels and safety...
9.
Gupta S, Hanna P, Ouyang T, Yamada K, Sawtell R, Wang Q, et al.
J Natl Cancer Inst
. 2023 Apr;
115(7):831-837.
PMID: 37074956
Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment of ovarian cancer; however, real-world data on kidney function among patients treated with PARPi are lacking. Methods: We identified adults...
10.
Hanna P, Wang Q, Strohbehn I, Moreno D, Harden D, Ouyang T, et al.
medRxiv
. 2023 Jan;
PMID: 36711583
Background: Creatinine-based estimated glomerular filtration rate (eGFR) may overestimate kidney function in patients with cancer. Cystatin C-based eGFR (eGFR) is an alternative marker of kidney function. We investigated whether patients...